Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
Clinical trial NCT07487519 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07487519
- Sponsor
- Shanghai Henlius Biotech
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-25
- Primary completion
- 2027-05-15
- Enrollment
- 180
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.